Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 5Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 98Lymphoid 48Other hematologic neoplasm 37Thoracic 7Genitourinary 6Gastrointestinal 5CNS 4Breast 4Tumor-Agnostic 3Myeloid 3Gynecologic 2Other solid neoplasm 1Head & Neck 1Endocrine 1Classical hematology 1

Conditions

beta-Thalassemia 1Thalassemia 1Anemia, Sickle Cell 1

Interventions

Cyclophosphamide 11fludarabine phosphate 8fludarabine 8apixaban 7Mycophenolic Acid 6Melphalan 6Busulfan 6Whole-Body Irradiation 4Tacrolimus 4Rivaroxaban 4Filgrastim 4Biopsy 4thymoglobulin 3X-Rays 3Specimen Handling 3Rituximab 3Peripheral Blood Stem Cell Transplantation 3Hematopoietic Stem Cell Transplantation 3Granulocyte Colony-Stimulating Factor 3Enoxaparin 3Bone Marrow Transplantation 3Azacitidine 3venetoclax 2pegylated granulocyte colony-stimulating factor 2olaparib 2Tretinoin 2Stem Cell Transplantation 2Mesna 2Injections 2Heparin, Low-Molecular-Weight 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Dexamethasone × Classical hematology × Clear all
NCT05736419 2026-04-08

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
24 enrolled
Classical hematology

Anemia, Sickle Cell, Thalassemia, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡